Bluephage

Summary

Bluephage's, patented, microbiological testing kits developed at University of Barcelona, easily detect Coliphages in water (newly recognized as viral indicators of un-safe water). Distributing to 15 countries globally, Bluephage are well placed to enter the €1.4 billion (2022) water testing market.

• Bluephage is the 1st water biotech company in Spain to become a B-Corp
• Commercializing patented technology, licensed to us by University of Barcelona
• Our coliphage, water testing kits help prevent water-borne diseases
• Distributing to 12 EU countries, Singapore, South Africa & Georgia

Operations

Bluephage was founded in 2016 as a spin-off from the University of Barcelona by renowned researchers from the Health-Related Water Microbiology Research Group (MARS).

Our goal is to help fight the global water crisis & becoming a B-Corp only helped to reinforce this.

In 2021, the European Commission recognized Coliphages as a new, viral indicator within water. Water free of Coliphages generally can be deemed safe. With this patented, disruptive technology, licensed to us by University of Barcelona, you can detect Coliphages in just 6hrs. This is critical in a global context where rapid testing can help save lives, and where water safety is a key driver of policy making.

Over the last year we've gone from focusing on R&D to commercializing a product that quickly tests water for Coliphages. We've raised over €1.3m through two private rounds and several public grants. We're expanding our distributor network internationally with a presence currently in 12 European countries, Singapore, South Africa, & Georgia. Further, Our work in this area has already been recognized by Water Europe, who awarded us their '2020 SME Innovation Award'.

We're now ready to launch the 'Rapid Kit' to wider markets and hope that the Crowdcube community will help us in distributing this technology to ensure safe water for a better world.

For everyone, for the planet, help us fight the water crisis!

Team

Bluephage's team of world-renowned experts in basic and applied microbiology and virology, tapping into years of knowledge and know-how honed at the University of Barcelona within the MARS research group who developed the patent.

Enric Queralt is co-founder and CEO of the company, with more than 20 years experience leading projects and companies in the water sector.

Anicet Blanch is co-founder and Part-time CTO of the company, and is also a Professor of Microbiology at the University of Barcelona.

Núria Guilera. is our Commercial Director. MSc in Chemistry from the University of Barcelona and many years experience working in laboratories.

Miram Pascual, Chief Quality Officer (CQO). Doctor in Biotechnology at the University of Barcelona, plus more than 8 years of experience in microbiological water quality monitoring.

Julia Martín. Responsible for product R&D. Doctor in Environmental Microbiology and Biotechnology at the University of Barcelona. Extensive experience in microbiological water quality assessment. Holder of a 2017 Torres Quevedo grant.

Mireia Azuara, Chief Press Officer (Part-time CPO) Specialized in corporate communication and sustainable communication strategies.

Risks

As with any investment, investing in Bluephage carries a level of risk. Overall, based on the key risks highlighted below, the degree of risk associated with an investment in Bluephage is higher than in a company that's trading on a public market.

Early-stage investment

Bluephage is at one of the earliest stages of the business lifecycle, and the failure rate of companies at that stage is usually much higher than those at a later stage.

Illiquid investment

The number of transactions in shares of private companies is usually significantly lower than in public companies, typically resulting in it taking longer to sell shares in private companies at a price that is at least equal to the price that the shares were bought at. Accordingly, the Bluephage investment opportunity is considered to be higher risk than more liquid companies.

Actions

To invest in Bluephage, click here.

To contact Bluephage, click here.